Day 1 Monday, May 10
8:50 Welcome:
Suzanne Tomlinson, Gulf Coast Consortia
Convener: Scott Gilbertson, University of Houston
9:00 Keynote Address:
Discovery and Development of GPCR Allosteric Ligands: From Concept to Clinic
Craig Lindsley, Vanderbilt
Session 1: HT Discovery
Conveners: Cliff Stephan, Institute of Biosciences & Technology, Texas A&M Health Science Center
Margie Moczygemba, Institute of Biosciences & Technology, Texas A&M Health Science Center
9:40 Assay and Screening Strategies for Chemical Probe and Drug Discovery
James Inglese, NIH/NCATS
10:10 High Throughput Flow Cytometry for Drug Discovery and Repurposing
Larry Sklar, University of New Mexico
10:40 The Evolution of a Fully Automated High Throughput Flow Cytometry Screening System to Enable Drug Discovery
John Joslin, Novartis
11:10 Networking Break
Session 2: Advanced Imaging for Target Validation and Drug Discover
Convener: Mike Mancini, Baylor College of Medicine
11:25 Single Cell Analysis of Estrogen Receptor Actions
Fabio Stossi, Baylor College of Medicine
11:45 Implementing Deep Neural Network Technologies Across Experimental Scales
Reid Powel, Institute of Biosciences & Technology, Texas A&M Health Science Center
11:55 Microscopy-Based Identification of RNA Foci Modulators in Myotonic Dystrophy Type 1
Sara Jane Johnson, Baylor College of Medicine
12:05 High-throughput Imaging and a Multi-omics Approach Shed Light on Cisplatin Resistance
Vlad Sandulace, Baylor College of Medicine
12:15- Poster Session-Odd numbered posters
12:55
12:55 Lunch and Networking Break
Session 3: Metabolism-Targeted Therapeutics
Convener: Peter Davies, Institute of Biosciences & Technology, Texas A&M Health Science Center
1:30 The Role of Oxidative Phosphorylation (OXPHOS) in Metastasis and Therapeutic Resistance in Melanoma
Mike Davies, MD Anderson Cancer Center
2:00 IACS-6274, a Potent and Selective Inhibitor of Glutaminase (GLS1) Being Developed for KEAP1/NFE2L2 Mutant NSCLC and ASNS-low Ovarian Cancer Patients
Nakia Spencer, MD Anderson Cancer Center
2:30 Optical Metabolic Imaging to Quantify Heterogeneity in Anti-Cancer Drug Response
Alexandra Walsh, Texas A&M University
3:00 Networking Break
Session 4: PK/PD and Formulation
Conveners: Diana Chow, University of Houston
Dong Liang, Texas Southern University
3:15 Development of AZD5305, The Next Generation PARP1 Selective Inhibitor and Trapper
Elisabetta Leo, Astrazeneca
3:45 Overcoming Transport Barriers in Cancer Treatment
Haifa Shen, Houston Methodist
4:15 Preclinical and Clinical PK/PD/Efficacy Work on the OxPhos Inhibitor IACS-010759, Targeting Metabolic Vulnerabilities in Cancer
Emilia Di Francesco, MD Anderson Cancer Center
Convener: Suzanne Tomlinson, Gulf Coast Consortia
4:45 CPRIT Update and Company Funding Opportunities
Cindy WalkerPeach, CPRIT
5:15 Core Facility Networking Showcase
- Center for Drug Discovery (Marty and Damian)
- Combinatorial Drug Discovery (Pete and Cliff)
- PK/PD and Formulation (Liang)
- Advanced Microscopy (Mancini)
- High-throughput Flow Cytometry Core Facility (Moczygemba)
- Therapeutic Monoclonal Antibody (An)
- Accelerating Cancer Therapeutics (Business accelerator; Luby, Hein, Watowich)
- Targeted Therapeutics Drug Discovery Program (UT Dalby)
- Center for Innovative Drug Discovery (McHardy)
Day 2 Tuesday, May 11
9:00 Welcome Phil Jones, MD Anderson Cancer Center
Session 5: Breakthrough Medicines originating from Academic Drug Discovery
Convener: Phil Jones, MD Anderson Cancer Center
9:00 Towards the Rational Design and Development of Targeted Protein Degraders
Lyn Jones, Dana-Farber Cancer Institute
9:30 Drugging Protein-protein Interactions: Discovery and Optimization of WDR5 Binders
Rima Alawar, Ontario Institute for Cancer Research
10:00 Drugging RAS: Meeting the Challenge
Alex Waterson, Vanderbilt University
10:30 Networking Break
Session 6: Biotech Start-ups
Convener: Sarah Hein, Texas Medical Center, Accelerator for Cancer Therapeutics
10:45 TMC Accelerator for Cancer Therapeutics: Supporting the Texas Biotech Ecosystem
Sarah Hein, Texas Medical Center, Accelerator for Cancer Therapeutics
ACT Users:
11:05 Raimund Ober, Astero Alta
11:15 Andrew Koh, Aumenta
11:25 Craig Ramirez, Tezcat
11:35 Tvardi Therapeutics: Tvardi Therapeutics: The Next Generation of Texas Companies Advancing Through Clinical Trials for Cancer and Fibrosis of Texas
Imran Alibhai, Tvardi Therapeutics
11:55- Poster Session-Even numbered posters
12:35
12:35 Lunch/networking break
Convener: Phil Jones, MD Anderson Cancer Center
1:45 Keynote Address:
East to West: A Career in Cancer Care and Drug Discovery
Tom Lynch, Fred Hutch
Session 7: Cell Therapies
Convener: Stan Watowich, University of Texas Medical Branch
2:30 CAR-modified Virus-specific T-cells for the Treatment of Malignancies: Taking Advantage of the TCR
Cliona Rooney, Baylor College of Medicine
3:00 MDACC’s Approach to Optimizing the Academic/Industrial Interface in Cell Therapy
Jason Bock, MD Anderson Cancer Center
Session 8: Future Directions and Opportunities: Technologies, Trends, Etc.
Convener: Stan Watowich, University of Texas Medical Branch
3:30 Keynote Address:
Academic Entrepreneurs, New Technologies, and Building a Biotechnology Ecosystem: A Personal History
Harvey Lodish, Massachusetts Institute of Technology
4:15 Closing Remarks
Suzanne Tomlinson, Gulf Coast Consortia
Stan Watowich, UT Medical Branch at Galveston